Basic Information


GTO ID GTC0425
Trial ID NCT03480152
Disease Hepatocellular Carcinoma | Genitourinary Cancer | Colon Cancer | Melanoma
TherapymRNA vaccine
Treatment NCI-4650
PhasePhase1|Phase2
Recruitment statusTerminated
TitleA Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Year2018
CountryUnited States|Canada
Company sponsorNational Cancer Institute (NCI)
Other ID(s)180074|18-C-0074
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: NCI-4650_dose level 1
Administration route intramuscular injection
Dosage NCI-4650, 0.13mg, Days 0, 14, 28, and 42
Pts 2
Age Adult, Older_Adult
Outcome 0/2(CR); 0/2(PR)
Adverse reactions No serious clinical adverse events
References PMID: 33016924
Cohort2: NCI-4650_dose level 2
Administration route intramuscular injection
Dosage NCI-4650, 0.39mg, Days 0, 14, 28, and 42
Pts 2
Age Adult, Older_Adult
Outcome 0/2(CR); 0/2(PR)
Adverse reactions No serious clinical adverse events
References PMID: 33016924

Relationship Graph

Overview of Knowledge Graph